Abstract 6711: Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergizein vitroand potentiatein vivoanti-tumor activity in multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-6711
Abstract: Multiple myeloma (MM) is a hematological malignancy that affects plasma cells and leads to devastating clinical features. Typically, front-line and relapsed/refractory multiple myeloma (RRMM) treatments comprise standard of care (SOC) combinations that include proteasome inhibitors… read more here.
Keywords: lenalidomide pomalidomide; multiple myeloma; belantamab mafodotin; cell ... See more keywords